Smoking Cessation for Pregnant Smokers: Development and Pilot Test of an Emotion Regulation Treatment Supplement to Standard Smoking Cessation for Negative Affect Smokers.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

Negative affect has been identified as a factor influencing continued smoking during pregnancy.

In this study, a multi-component emotion regulation intervention was developed to address negative emotional smoking triggers and pilot-tested among low-income pregnant smokers.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, women only.

Treatment feasibility and acceptability, cotinine-verified rates of smoking cessation, and self-report of mean cigarettes smoked were assessed.

Pregnant smokers who self-reported smoking in response to negative affect (N = 70) were randomly assigned to receive one of two 8-session interventions: (1) emotion regulation treatment combined with standard cognitive-behavioral smoking cessation (ERT + CBT) or (2) a health and lifestyle plus standard smoking cessation active control (HLS + CBT).

How the Study Was Run

In design terms this was a randomized and pilot study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

Outcomes for the 4-month period following the quit date are reported.

What Was Measured

In this study, a multi-component emotion regulation intervention was developed to address negative emotional smoking triggers and pilot-tested among low-income pregnant smokers.

PubMed files the paper under topics including Affect, Cognitive Behavioral Therapy, Cotinine, Emotions, Feasibility Studies, Motivation and Patient Acceptance of Health Care.

What This Means in Plain Language

The paper is a randomized and pilot study of Copper (Supplement).

Its findings take up roughly 13 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.